Advances in knowledge regarding the pathogenesis of psoriasis have allowed the 
development of a new class of agents known as biologic drugs. Data confirm that 
T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the 
pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines 
have been reported in psoriasis, leading to the suggestion of agents targeting 
IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human 
monoclonal antibody that targets IL-17 receptor A, blocking the effects of 
IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials 
indicate that brodalumab has a favorable safety and tolerability profile, with 
strong clinical activity, suggesting that it is a potential tool for use in the 
treatment of moderate-to-severe psoriasis.